Главная Назад


Авторизация
Идентификатор пользователя / читателя
Пароль (для удалённых пользователей)
 

Вид поиска

Область поиска
в найденном
Найдено в других БД
Формат представления найденных документов:
библиографическое описание краткийполный
Отсортировать найденные документы по:
авторузаглавиюгоду изданиятипу документа
Поисковый запрос: (<.>S=АРГАТРОБАН<.>)
Общее количество найденных документов : 26
Показаны документы с 1 по 20
 1-20    21-26 
1.
Ansara Alexander J. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia // Ann. Pharmacother., 2009. Vol. 43, N 1.-С.9-18, 114-117

2.
Ansara Alexander J. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia // Ann. Pharmacother., 2009. Vol. 43, N 1.-С.9-18, 114-117

3.
Vascular surgery using argatroban in a patient with a history of heparin-induced thrombocytopenia // Circ. J., 2003. Vol. 67, N 10.-С.889-890

4.
Vascular surgery using argatroban in a patient with a history of heparin-induced thrombocytopenia // Circ. J., 2003. Vol. 67, N 10.-С.889-890

5.
Study of the pharmacological effect of the bile salt, sodium scymnol sulfate, from Rhizoprionodon acutus II: Prophylactic effect of scymnol on lesion development in a rat peripheral arterial occlusion model // Biol. and Pharm. Bull., 1998. Vol. 21, N 3.-С.240-244

6.
Reduced argatroban doses after coronary artery bypass graft surgery // Ann. Pharmacother., 2008. Vol. 42, N 3.-С.309-316

7.
Recanalization of acute occlusion after percutaneous transluminal coronary angioplasty (PTCA) using a synthetic thrombin inhibitor, argatroban // Fibrinolysis, 1994. Vol. 8, Suppl. n 1.-С.74

8.
Prolonged half-life of Argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia // Amer. J. Hematol., 2008. Vol. 83, N 3.-С.245-246

9.
Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition // Circulation, 1990. Vol. 81, N 1.-С.219-225

10.
Hantgan Roy R. No effect of clot age or thrombolysis on agratroban's inhibition of thrombin // Blood, 1998. Vol. 92, N 6.-С.2064-2074

11.
Balasa Vinod V. New anticoagulants: A pediatric perspective // Pediat. Blood and Cancer, 2005. Vol. 45, N 6.-С.741-752

12.
Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia // Ann. Pharmacother., 2009. Vol. 43, N 1.-С.19-27

13.
Effect of Argatroban on the formation of artificial thrombus on dogs // Int. J. Tissue React., 1995. Vol. 17, N 3.-С.109-116

14.
Dager William E. Considerations for drug dosing post coronary artery bypass graft surgery // Ann. Pharmacother., 2008. Vol. 42, N 3.-С.421-424

15.
Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia // Pharmacotherapy, 2010. Vol. 30, N 12.-С.1229-1238

16.
Combined administration of aspirin and a specific thrombin inhibitor in man // Circulation, 1991. Vol. 83, N 5.-С.1510-1518

17.
Samama C.M. Coagulation intravasculaire disseminee (CIVD) Nouvelles modalites de traitement // J. eur. urgences., 1992. Vol. 5, N 4.-С.213-217

18.
Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using HPLC and functional methods // Fibrinolysis and Proteolysis, 1998. Vol. 12, Suppl. n1.-С.78

19.
Clinical experience of Argatroban for anticoagulation in cardiovascular surgery // Nihon kyobu geka gakkai zasshi, 2000. Vol. 48, N 1.-С.39-46

20.
Argatroban therapy in pediatric patients requiring nonheparin anticoagulation. An open-label, safety, efficacy, and pharmacokinetic study // Pediat. Blood and Cancer, 2011. Vol. 56, N 7.-С.1103-1109

 1-20    21-26 
 




© Международная Ассоциация пользователей и разработчиков электронных библиотек и новых информационных технологий
(Ассоциация ЭБНИТ)